Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

In the latest episode of the “Pharmacy Friends” podcast, hear from Prime Therapeutics experts about how the fast-moving pipeline is changing how patients, providers and payers prepare for...

Unlock high-touch outreach Help members and their prescribers make better decisions about medicines through this clinical intelligence hub that delivers actionable insights, flexible levels of data...

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this...

Insights from Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Jessica Johnson, clinical consultant, shares how the Special Investigations Unit at Prime helps identify cases of fraud

Drug Approvals Monthly Update: January 2024 Traditional New drugs 1/05/2024 Zelsuvmi™ (berdazimer): The FDA approved Zelsuvmi for the topical treatment of molluscum contagiosum (MC) in adult and...

Prime Therapeutics experts explore how health plans expand access to GLP-1 therapies while maintaining affordability, clinical oversight and long-term sustainability

Drug Approvals Monthly Update: February 2024 Specialty New drugs 2/16/2024 Amtagvi™ (lifileucel) The United States (U.S.) Food and Drug Administration (FDA) approved the first-in-class...

In the latest episode of the “Pharmacy Friends” podcast, hear more about what faster drug decisions could mean for evidence review, affordability assessment and implementation planning

Reversal in obesity rate syncs with rising usage of expensive GLP-1 medications, but whether the trend will continue in Minnesota is unclear.

Home News & Insights Research & publications Drug Approvals Drug Approvals Monthly Update: September 2024 1. ADvocate 1 and 2 trials: https://pubmed.ncbi.nlm.nih.gov/36920778/ 2. ADhere trial:...

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Read Drug Approval Update Specialty New drugs 06/06/2024 Rytelo™ (imetelstat) The FDA approved the first-in-class oligonucleotide telomerase inhibitor, Rytelo, for the treatment of adults with low-...

Specialty New drugs 3/18/2024 Lenmeldy™ (atidarsagene autotemcel) Lenmeldy is an autologous hematopoietic stem cell-based gene therapy by Orchard Therapeutics, which was FDA approved for the...

As use of GLP-1 therapies grows, new data shed light on the challenges of sustaining treatment over time

Read Drug Approval Update Specialty New drugs 04/22/2024 Anktiva® (nogapendekin alfa inbakicept-pmln) The FDA approved Anktiva for use in combination with Bacillus Calmette-Guérin (BCG) for the...

Prime to present seven studies and receive the 2024 JMCP Award for Excellence